US Panel Revisits Lash Serum Prostaglandin Analogues
CIR posted a revised Draft Tentative Report on 11 September 2026 covering ethyl Tafluprostamide and isopropyl Cloprostenate — synthetic prostaglandin analogues used in some eyelash and eyebrow formulas.[1]
What changed
The file has a long history of insufficient-data announcements and a 2024 pause while industry studies were promised. Staff say new toxicology, exposure, and ophthalmology-related materials have been folded into the revised draft for the October meeting; the written conclusion is still blank.[1]
Separately, the EU Scientific Committee on Consumer Safety concluded in February 2026 that three prostaglandin analogues assessed for lash and brow growth — including isopropyl cloprostenate — could not be considered safe for that use, citing potent pharmacology and gaps on adverse effects.[2] Ethyl tafluprostamide was outside that specific trio, but it sits in the same analogue class.
Why it matters
Lash serums that list these INCIs are closer to drug-class chemistry than to bland conditioners. Shoppers should read labels for concentration and ocular-risk language and watch what the US Panel decides in October.[1][2]
Sources
- Cosmetic Ingredient Review. Revised Draft Tentative Report on Ethyl Tafluprostamide and Isopropyl Cloprostenate (release 11 Sep 2026). https://www.cir-safety.org/sites/default/files/Prostaglandin%20Analogues_0.pdf
- SCCS. Opinion on prostaglandin analogues used in cosmetic products, SCCS/1680/25 (final 2 Feb 2026). https://health.ec.europa.eu/publications/sccs-prostaglandin-analogues-methylamido-dihydro-noralfaprostal-mdn-isopropyl-cloprostenate-ipcp_en
Sources · 2
- [1]Revised Draft Tentative Report: Safety Assessment of Ethyl Tafluprostamide and Isopropyl Cloprostenate as Used in Cosmetics. Cosmetic Ingredient Review (2026)
- [2]SCCS / European Commission. Opinion on prostaglandin analogues used in cosmetic products (SCCS/1680/25). SCCS (2026)